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Abstract 
Background: 
Patients with neurofibromatosis type 2 and bilateral vestibular schwannoma (VS) are frequently 
treated surgically for any tumor progression, and often repeated surgery or radiation treatment is even 
considered. Some VS progression occurs without the development of new clinical symptoms, or it 
does not progress in size over many years, even in the absence of any specific treatment.  
Case Description: 
We report now a 61-year-old male patient with neurofibromatosis type 2 presenting with bilateral VS. 
In a long-term follow-up, both had increased in size but also showed bilateral spontaneous regression 
during an 11-year follow-up period with a "watch and wait" strategy. 
Conclusions: 
We emphasize conservative treatment (“watch and wait”) in older patients even with long-term tumor 
progression without significant compression related clinical symptoms. 
 
 
 
Key words: conservative management, magnetic resonance imaging, neurofibromatosis type 2, 
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Introduction 
Neurofibromatosis type 2 (NF2) often occurs with unilateral or bilateral vestibular schwannomas (VS). 
[1] Natural history studies of VS have shown disease progression over time, although the rate of 
progression varies, and symptoms are not necessarily directly correlated with tumor growth. [2, 3]  For 
instance, Mautner et al. [4] in their longitudinal study concluded that VS growth rates in NF2 tend to 
decrease with increasing age. Moreover, some VS progress without coinciding progressive clinical 
symptoms, whereas others are stable over many years, even in the absence of treatment. [3, 5-7] 
Particularly, approximately only 20-35 per cent of sporadic VS grow after diagnosis, although this 
percentage is higher in NF2. [8, 9] Therefore, the question how to manage VS is of crucial importance 
in the treatment of the disease. Management options include the conservative '‘watch and wait" 
strategy, surgery, radiation, and chemotherapy. [10] Although progressively growing tumors are 
frequently treated immediately, irrespective of progressive symptomology, [11] it has been questioned 
if every progression should be treated.[9] Especially in the older population, one can opt for a "watch 
and wait" strategy.   
 
In this case report, we report on an elderly patient with the bilateral spontaneous regression of initially 
growing VS in NF2 during an 11-year period of a “watch and wait” strategy.  
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Case report 
Presentation, history, and examination findings. 
A 61-year-old patient with NF2 and bilateral VS, an intraventricular meningioma on the right side, three 
falx meningiomas, and thoracal and lumbal neurinomas (Th2, Th5 and L3) consulted our 
neurosurgical department for the first time in 2006. Already in the 1980s, the patient suffered from 
deafness on the left side. NF2 was confirmed with genetic tests without prior family history. The first 
presentation at our hospital was in the 1990s at the department of otorhinolaryngology with acute 
partial hearing loss on the right side. In 2009, an audiogram showed moderate sensorineural hearing 
loss on the right side. A magnetic resonance imaging (MRI) study of the brain revealed stationary 
bilateral VS (Figure 1). The other tumors showed no mass effect, and therefore, a surgical intervention 
was not foreseen. The patient was also reticent regarding any treatment. Therefore, we went for a 
conservative “watch and wait” strategy and planned new clinical and radiological follow-ups. In the 
following years, frequent cerebral imaging showed a discrete progression of right-sided VS; the 
radiographic result correlated with progressive hearing loss. An audiogram showed a remaining 5% 
speech discrimination on the right side. In the long term, the right-sided VS showed a clear 
progression, and the left-sided VS showed no clear growth (Figure 1).  At this point, a possible 
intervention (surgery or radiotherapy) was discussed with the patient. The intent was to perform any 
kind of hearing-preserving treatment. The case was discussed in an interdisciplinary skull base 
conference, where the consensus was not to operate but rather to save the remaining hearing in the 
short term. The patient was also opposed to any kind of treatment. The follow-up MRI in 2015, two 
years later, showed that both VS were stable in size. At the most recent follow-up in May of 2017, 
however, the MRI images showed that the VS on both sides presented with spontaneous regression 
(on the right side: 5.8 x 8.5 mm, before: 6.4 x 11 mm; on the left side: 1.2 x 1.4 mm, before: 1.4 x 1.5 
mm) (Table 1). No treatment was initiated or administered and the medication history for supplement 
intake of patient (pharmaceutical or herbal), in particular BIO 100, was negative. 
With regard to his other intracranial mass lesions, the intraventricular meningioma and one of the falx 
meningioma were discretely progressive in size. The rest of the tumors was stable over the whole 
period. None showed signs of growth regression in any of the MR imaging.   
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Discussion 
Many studies on the natural history of VS in past decades mostly excluded patients with NF2. [12-14]. 
For instance, Stangerup et al. [8] studied the natural history of non-NF2-related VS; however, no 
reports of tumor regression were seen over a mean observation period of 3.6 years. Selesnick and 
Johnson [15] included 571 cases, of which 16 involved patients who had NF2. A total of 46% of the 
observed tumors showed no growth during a mean observation period of three years. There was no 
report of tumor regression.  
The mechanisms of spontaneous regression of VS are still unknown. Luetje [14] in his study 
hypothesized that the shrinkage of VS was due to spontaneous intratumoral vascular thrombosis and 
subsequent ischemic necrosis following fibrosis. A patient characteristic supporting the hypothesis is 
that the largest degree of tumor regression occurred in the patient presenting with the largest tumor.  
According to our experience, we discuss another hypothesis, which might explain spontaneous tumor 
regression. A lack of quality blood vessels for sustaining the blood supply in large tumors could be the 
possible genesis of the shrinkage of the right-sided VS in our case, which lost approximately one-third 
of its volume in the past year and was previously slowly progressive, especially in a long-term follow-
up.  
Another important fact in the treatment decision-making is age. Mautner et al. [4] published the trend 
of decreasing VS growth rate with increasing age. Maniakas et al. [16] reviewed 19 articles to assess 
the long-term outcome of the available treatment for VS in NF2 and reported that microsurgery seems 
to show the worse overall results, with half of the cases losing their useful hearing as well as half 
showing tumor recurrence. Stereotactic radiation showed very good tumor control with poor hearing 
preservation. They concluded, in agreement with our case, that conservative management continues 
to be the most benign treatment option with satisfactory results as long as tumor stability is ensured. 
Similarly, the results of a hypofractionated stereotactic radiosurgery outcome study by Teo et al. [17] 
for large VS speak for a “watch and wait” strategy. Among 587 patients, just six had NF2, but they 
appeared to have higher rates of tumor progression and less favorable functional outcomes compared 
with sporadic VS. 
This leads to an important question about the treatment of VS in patients with NF2. At which volume 
cut-off and by which clinical symptoms should treatment be initiated? Our patient initially showed long-
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term tumor progression without new neurological deficits in past years, after which spontaneous 
regression set in at some point.  
Especially in the older population, watch and wait strategy should be primarily considered, and we 
recommend surgery only in enlarging VS with compressive symptoms.  
 
Conclusion 
We report on a patient with bilateral spontaneous regression of VS in NF2 and emphasize 
conservative treatment (“watch and wait”) in older patients even with long-term tumor progression 
without significant clinical symptoms. 
 
Funding: This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
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Figure Captions 
Caption figure 1:  
Chronologic presentation of gadolinium-enhanced MRI with a two-year interval showing initial bilateral 
growth of both vestibular schwannomas and interestingly, bilateral spontaneous regression in 2017 
without any initiated treatment regimen. For illustrative purposes, we applied a voxel-to-voxel affine 
transformation to align all the acquired gadolinium-enhanced MRI using SPM 12 (Statistical Parameter 
Mapping Software, Wellcome Department of Imaging Neuroscience, University College of London, 
London, UK) 
 
Caption figure 2:  
Graph showing changes in volume (mm3) of left- and right-sided VS over the years. 
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Table 1. Volume (mm3) of left and right sided vestibular schwannoma over the years 
Year Left Right 
2007 260 557 
2009 278 676 
2010 323 878 
2011 315 1049 
2012 330 1023 
2013 370 1127 
2014 331 1363 
2015 330 1383 
2016 386 1387 
2017 249 827 
 
*The volume analysis of vestibular schwannoma in gadolinium-enhanced MR images was done with 
iPlan 3.0 ENT from Brainlab.  
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Highlights 
• Bilateral spontaneous regression of vestibular schwannoma in neurofibromatosis type 2 
without any treatment and any medication history. 
 
• In the older population, spontaneous regression should be taken into account. 
 
• Surgery only in progressive lesions with compression-related clinical symptoms that should 
resolve after treatment. 
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Abbreviation list: 
MRI – magnetic resonance imaging 
NF2 – neurofibromatosis type 2 
VS – vestibular schwannoma 
 
